Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Aipalolitovorilimab plus Tegio and Oxaliplatin for Metastatic Gastric Cancer
ChiCTR2500115675Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Objective Response Rate. Started Dec 2025; status: recruiting.
02
Drugs
pucotenlimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500115675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115675.